American Pharmaceutical Partners and American BioScience have reported that positive results were observed with dose-dense combination therapy in early-stage breast cancer patients who received AC (Adriamycin plus Cytoxan) followed by Abraxane as adjuvant treatment. Additionally, activity was observed in a combination study of Abraxane and carboplatin in multiple solid tumor types, including lung and breast cancer.
Preliminary results from the Phase II trial showed that dose-dense therapy with AC followed by dose-dense Abraxane was well-tolerated in patients with early stage breast cancer. The open-label pilot study was designed to evaluate the toxicity of AC therapy followed by Abraxane 260 mg/m2 every two weeks for four cycles each as adjuvant therapy in patients with early stage breast cancer. This study was conducted in preparation for a large randomized Phase III clinical trial.